Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer

Angelergues, Antoine; Maillet, Denis; Flechon, Aude; Ozguroglu, Mustafa; Mercier, Florence; Guillot, Aline; Le Moulec, Sylvestre; Gravis, Gwenaelle; Beuzeboc, Philippe; Massard, Christophe; Fizazi, Karim; Rouge, Thibault; Delanoy, Nicolas; Elaidi, Reza-Thierry; Oudard, Stephane

doi:10.1016/j.ejca.2014.03.015

Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer

Atıf İçin Kopyala

Angelergues A., Maillet D., Flechon A., Ozguroglu M., Mercier F., Guillot A., ...Daha Fazla

EUROPEAN JOURNAL OF CANCER, cilt.50, sa.9, ss.1602-1609, 2014 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 50 Sayı: 9
Basım Tarihi: 2014
Doi Numarası: 10.1016/j.ejca.2014.03.015
Dergi Adı: EUROPEAN JOURNAL OF CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1602-1609
İstanbul Üniversitesi Adresli: Evet

Özet

Background: A prostate-specific antigen (PSA) flare occurs in about 15% of metastatic castration-resistant prostate cancer (mCRPC) patients receiving docetaxel. This flare has no standard definition. Its impact on treatment efficacy is unclear. We sought to evaluate the incidence and characteristics of PSA flare on cabazitaxel, and its impact on survival.